Personalized Medicine — Europe | NovaPharmaNews

Breaking

Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD FDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup

RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035

NewsApr 25, 2026

RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035

RNA therapy clinical trials market hits $3.4B driven by delivery advances, rare disease funding, and personalized medicine growth through 2035.